11:59 AM EST - BriaCell Therapeutics Corp : Announces that it has received an Issue Notification from the United States Patent and Trademark Office for the composition of matter and method of use of its personalized off-the-shelf cell-based immunotherapy for cancer. The patent will issue on January 24, 2023 as US Patent No. 11,559,574 with the term extending to May 25, 2040. Additionally, BriaCell was awarded an Australian patent (Patent No. 2017224232, extends to February 27, 2037) covering composition of matter and method of use for its whole-cell cancer immunotherapy technology in Australia. BriaCell Therapeutics Corp
shares T.BCT are trading up $0.44 at $7.83.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=BCT%3ACA&qmodStoryID=8648639811174995
